tiprankstipranks
Trending News
More News >

Avalo Therapeutics sees cash runway into 2027

Cash and cash equivalents were $125.0 million as of March 31, 2025. Net cash used in operating activities was $9.5 million for the first quarter of 2025. The Company’s current cash on hand is expected to fund operations into at least 2027.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue